One example of many emerging NK cell-mediated regulatory roles in constraining T cell immunity against cancer. Science Immunology #NK_cell science.org/doi/10.1126/sc…

Congratulation to @beziatv et al. for a tour de force study showing that Flt3L deficiency strongly affects adult hematopoietic progenitors, B cells, monocytes and DC development while macrophages remained intact in humans. cell.com/cell/fulltext/…

Greetings, #PIIO ! We're selling Team Buckeye Raffle Tickets to raise funds for Pelotonia 2024. 100% of proceeds are dedicated to #cancer research at the
The James
. Please DM for more info. Please Retweet! cancer.osu.edu/for-donors-and…

Had a great visit to the Pelotonia Institute for Immuno-Oncology to discuss the power of the gut #microbiome in modulating anti-tumor immunity and response to #immunotherapy in cancer patients.
Schulich WesternU Western University Lawson Research

nature.com/articles/s4159…

Immunology is for everyone!
Excited to share 'Exploring new perspectives in immunology' with Ruslan Medzhitov in Cell.

sciencedirect.com/science/articl…

Yes we can!!

Of 35 patients with transfusion-dependent β-thalassemia treated with gene-edited autologous hematopoietic stem and progenitor cells, 32 had hemoglobin levels maintained without red-cell transfusions for at least 12 consecutive months. Full study results: nej.md/3xYXrI1

The moment is here. Didn’t we all dream about this as medical students?

We previously showed that platelets repress T cell function via GARP-mediated activation of latent TGFb (PMID 28763790 and 31915300). The current two studies suggest that PGE2 released by activated platelets can also blunt anti-tumor CD8+ T cells.

Congratulations to Carl June, awarded the Breakthrough in Life Sciences for the development of #CARTcelltherapy , a revolutionary cancer treatment in which a patient’s own T cells are modified to target and kill their cancer cells.

This is a great look at just a few of the important #immunotherapy efforts underway at the The James, where our Pelotonia Institute for Immuno-Oncology team works every day to break new ground in this growing field of #cancer care.

Meet Dr. Mark Rubinstein Pelotonia Institute for Immuno-Oncology, a brilliant mind whose foundational work (PNAS 2006, PMID: 16757567; Blood 2008, PMID: 18689546; Lancet Oncol 2018, PMID: 29628312; JI 2022, PMID: 35228263) led to U.S. FDA approval of ImmunityBio, Inc. #ANKTIVA , a FIC IL-15R agonist for NMIBC.

Nice to be home. City of Columbus Delaware County, Ohio Pelotonia Institute for Immuno-Oncology

Amazing science, great people and a venue with unmatched beauty - it was a total joy and honor to attend the 2024 conference on sexual dimorphism in cancer in @communeLausanne. Thank you GianPaolo, An Buckinx, Susanna Chiocca, Adriana Maggi, Berna Ozdemir.

Excited to hear Jordan Krull, 2023 Pelotonia Postdoctoral Scholar, present on how #DeepLearning is revolutionizing digital pathology! His insights on extracting crucial numerical features from pathology slides are reshaping medical diagnostics. Zihai Li, MD, PhD Qin Ma BMBL #IOIG #PIIO

Great to hear from Anna Dart from Nature Reviews Cancer on publishing and a focus on #sexdifferences and #cancer - including our recent perspective on sex bias in immune responses with Zihai Li, MD, PhD Juyeun Lee Tong Xiao

Congrats to Amer Lab and all!!

Very excited to participate in this conference and meet with who is who in the field in person: Second International Conference on #SexualDimorphism in Cancer – International Cancer Prevention Institute cancerprev.ch/conference-sd-…